![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Thursday, January 06, 2022 10:12:56 AM
In partnership, the companies will develop co-exclusive, co-branded, next-generation sequencing (NGS)-based proteomics products.
The companies will leverage the power and scale of Illumina’s global commercial infrastructure and SomaLogic’s unique proteomics platform, which includes its proprietary synthetic aptamer reagents capable of measuring and identifying 7,000 human proteins, unique bioinformatics tools and capabilities, and a clinical proteomics database, believed to be the largest in the world.
“This is truly a transformational partnership that will democratize and accelerate our understanding of the human proteome,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “It definitively signals that the era of proteomics is here and that SomaLogic, and now Illumina, will lead that era. The combined capabilities of our two companies—the scientific and commercial leaders in both next-generation genomic sequencing and proteomics—will inevitably have a profound impact on the understanding, avoidance and treatment of human disease. This has always been our goal at SomaLogic, and we could not be more excited to be working together with Illumina to continue to fulfill it—more quickly and more comprehensively.”
The partnership brings together unique capabilities from each company for customers in research, clinical and applied markets. Illumina is a global leader in DNA sequencing and array-based technologies. SomaLogic has a 20-year history of using slow off-rate modified aptamers, called SOMAmer® reagents, and its proprietary SomaScan® Platform to provide highly reproducible measurements of circulating proteins.
As part of the agreement, Illumina will develop and deploy NGS-based protein identification and measurement tools into laboratories worldwide, and facilitate the development and use of high-plex protein pattern recognition tests. SomaLogic pioneered this diagnostic approach, launching its SomaSignal™ test program in 2019. The company now offers 12 laboratory-developed protein pattern recognition tests across a diverse set of human conditions and diseases.
“Proteins play a central role in cellular function and health, and NGS can support a greater understanding of this role by unlocking biological insights at scale,” said Alex Aravanis, Chief Technology Officer at Illumina. “We are committed to increasing the utility of NGS, and our partnership with SomaLogic will enable existing and future NGS customers to conduct even more sophisticated, high throughput multiomic studies.”
SomaLogic can currently run 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has plans to expand their reagents and assay to measure 10,000 proteins in the next year. SomaLogic has run more than 450,000 samples to date.
The financial terms of the deal were not disclosed.
New York Yankees and Duke Basketball
Recent SLGC News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/16/2024 01:00:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/12/2024 05:15:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 02:54:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 02:48:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 02:33:35 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/09/2024 10:16:22 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/05/2024 09:43:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/05/2024 09:40:36 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/05/2024 09:39:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:33:50 PM
- Standard BioTools Stockholders Approve Merger with SomaLogic • GlobeNewswire Inc. • 01/05/2024 03:23:06 AM
- SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting • PR Newswire (US) • 01/05/2024 02:44:00 AM
- Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting • Business Wire • 01/04/2024 11:57:00 PM
- Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools • Business Wire • 01/04/2024 07:23:00 PM
- Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools • Business Wire • 01/03/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 10:05:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 10:04:46 PM
- SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools • PR Newswire (US) • 01/02/2024 01:00:00 PM
- Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures • Business Wire • 12/30/2023 12:10:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/29/2023 10:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 10:29:42 PM
- Leading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools • PR Newswire (US) • 12/29/2023 09:42:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM